Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

891 results about "Transmembrane domain" patented technology

Transmembrane domain usually denotes a transmembrane segment of single alpha helix of a transmembrane protein. More broadly, a transmembrane domain is any membrane-spanning protein domain.

Engineered viral like particles (EVLPS) for the selective transduction of target cells

The present disclosure provides compositions and methods for the selective transduction and genome editing of human cells (e.g., hematopoietic stem and progenitors cells, HSPCs) using engineered viral like particles (eVLPs). Aspects of the disclosure provide eVLP compositions comprising fusion proteins comprising a targeting moiety. In some embodiments, the fusion proteins comprise a cytokine conjugated to a transmembrane protein and / or an envelope glycoprotein. In other embodiments, the fusion proteins comprise a targeting moiety domain, a stalk protein domain, a transmembrane and / or envelope glycoprotein domain. Targeted-eVLP architectures comprising various targeting domains, stalk domains, transmembrane domains, and envelope glycoproteins are also provided herein. Other aspects of the disclosure provide eVLP compositions comprising envelope glycoproteins comprising non-natural sugars and methods of conjugating said eVLPs to various targeting moieties using bio-orthogonal click chemistry. Polynucleotides, vectors, cells, and kits useful for producing the articles, and performing the methods, described herein are also provided.
Owner:THE BROAD INST INC +1

CA9-targeted chimeric antigen receptor and application thereof

The invention discloses a CA9-targeted chimeric antigen receptor and application thereof, and belongs to the technical field of biological medicines. The CA9 targeting chimeric antigen receptor provided by the invention comprises a CD8 alpha leading signal peptide, an anti-CA9 single-chain variable fragment, a CD8 alpha hinge, a CD8 transmembrane structural domain and a CD3 zeta intracellular costimulatory signal transduction structural domain. According to the invention, an anti-CA9 single-chain variable fragment is used as an antigen binding structural domain to construct a chimeric antigen receptor (CAR) molecule, the macrophage expressing the anti-CA9CAR can realize specific targeting and phagocytosis killing of CA9 positive kidney cancer cells, and the constructed lipid nanoparticle delivery system can effectively transfer a gene expression vector, so that the gene expression vector can realize effective target site delivery, and the CA9 positive kidney cancer cells can be effectively targeted and killed. The constructed hydrogel-liposome combined drug delivery system has the performance of relieving toxic and side effects, controllable release and hemostasis.
Owner:LIFE VALLEY (QINGDAO) HEALTH TECHNOLOGY CO LTD

Bispecific chimeric antigen receptors targeting CD20 and BCMA

The present disclosure provides bispecific chimeric antigen receptors targeting CD20 and BCMA. The CAR may comprise an scFv targeting CD20 and an scFv targeting BCMA, a hinge region, a transmembrane domain, a co-stimulatory region, and a cytoplasmic signaling domain. The chimeric antigen receptors can be used to treat autoimmune disorders or cancer.
Owner:ABELZETA INC

Nectin-4-targeting nano antibody, chimeric antigen receptor CAR and application

The invention belongs to the technical field of biology, and provides a nanometer antibody targeting Nectin-4, and a nucleic acid molecule and an expression vector for coding the nanometer antibody targeting Nectin-4. The invention also provides a chimeric antigen receptor which comprises an extracellular antigen binding domain, a transmembrane domain and an intracellular domain, and the extracellular antigen binding domain is a Nectin-4 nano antibody; the invention also provides a chimeric antigen receptor CAR which contains the nano antibody as scFv and co-expresses CXCR1, a CAR-T cell constructed by the chimeric antigen receptor CAR, and an enhanced CAR-T cell obtained by modifying the CAR-T cell with microbial short-chain fatty acid, so as to improve the infiltration and anti-tumor activity of the CAR-T cell targeting Nectin-4.
Owner:THE FIRST AFFILIATED HOSPITAL OF WANNAN MEDICAL COLLEGE (YIJISHAN HOSPITAL OF WANNAN MEDICAL COLLEGE)

Modified vaccine design development

Provided herein are isolated polynucleotides encoding a polypeptide comprising an antigen protein fused to a signal sequence and a transmembrane domain, and optionally fused to a ferritin. Also provided herein are isolated polynucleotides encoding alphaviral non-structural proteins nsp1, nsp2, nsp3, and nsp4 and polypeptides comprising an antigen protein fused to a signal sequence and a transmembrane domain, and optionally fused to a ferritin. The antigen may be influenza. Polynucleotides, such as RNAs, can be used as vaccines against influenza infection.
Owner:VLP THERAPEUTICS JAPAN INC

Synthetic self-amplifying mRNA molecules with secretory antigens and immunomodulators

Lipid nanoparticles (LNPs) encapsulating self-amplifying mRNA, compositions, and methods of use of the novel nucleic acid constructs and compositions are disclosed. The LNP constructs comprise a novel ionizable lipid. The novel sa-mRNA constructs encode a modified SARS-CoV-2 spike protein in which the polynucleotide has been truncated to comprise no nucleotides encoding SARS-CoV-2 transmembrane domain and short cytoplasmic domain amino acids, as well as immunomodulators. The sa-mRNA may be used as a therapeutic, diagnostic and / or prophylactic agent for mammalian cells or organs.
Owner:SUNVAX MRNA THERAPEUTICS INC

Bispecific chimeric antigen receptors targeting BCMA and CD19

The present disclosure provides bispecific chimeric antigen receptors that target BCMA and CD19. The CAR may comprise an scFv targeting BCMA and an scFv targeting CD19, a hinge region, a transmembrane domain, a co-stimulatory region, and a cytoplasm signaling domain. Chimeric antigen receptors can be used to treat autoimmune disorders or cancer.
Owner:CIBMAN BIOTECHNOLOGY GRP

Preparation and application of target LYPD3 chimeric antigen receptor T cell

The invention discloses preparation and application of a targeting LYPD3 chimeric antigen receptor T cell. The chimeric antigen receptor comprises an LYPD3 antigen binding domain, a transmembrane domain, a costimulatory signal transduction domain and an intracellular signal transduction domain, the LYPD3 antigen binding domain comprises a heavy chain variable region with CDR-H1, CDR-H2 and CDR-H3 and a light chain variable region with CDR-L1, CDR-L2 and CDR-L3, and the CDR-H1, the CDR-H2 and the CDR-H3 are respectively composed of amino acid sequences of SEQ ID NO: 3, SEQ ID NO: 4 and SEQ ID NO: 5. And the CDR-L1, the CDR-L2 and the CDR-L3 are respectively composed of amino acid sequences as shown in SEQ ID NO: 6, SEQ ID NO: 7 and SEQ ID NO: 8.
Owner:SUZHOU INST OF SYST MEDICINE

Compound chimeric antigen receptor (CCAR) targeting multiple antigens, compositions and methods of use thereof

In one embodiment, the present disclosure provides an engineered cell having a first chimeric antigen receptor polypeptide including a first antigen recognition domain, a first signal peptide, a first hinge region, a first transmembrane domain, a first co-stimulatory domain, and a first signaling domain; and a second chimeric antigen receptor polypeptide including a second antigen recognition domain, a second signal peptide, a second hinge region, a second transmembrane domain, a second co-stimulatory domain, and a second signaling domain; wherein the first antigen recognition domain is different than the second antigen recognition domain.
Owner:ICELL GENE THERAPEUTICS LLC

Insect adenosine triphosphate binding cassette superfamily transport protein and application thereof

The invention relates to an insect adenosine triphosphate binding cassette superfamily transport protein and application thereof. The insect adenosine triphosphate binding cassette superfamily transporter is a homodimer, and each monomer has an adenosine triphosphate binding and hydrolysis structural domain, a transmembrane structural domain containing 6 transmembrane helixes and an extracellular structural domain; in a transmembrane structure domain of the protein structure, a spiral 1, a spiral 2 and a spiral 5 of each monomer form an arched substrate binding channel. Experiments show that the adenosine triphosphate binding cassette superfamily transporter and a pesticide micromolecule substrate are bound in the arched substrate binding channel and are discharged out of a body, so that drug resistance is generated, and the transport protein can be used for treating the pesticide micromolecule substrate. Therefore, the insect adenosine triphosphate binding cassette superfamily transport protein can be used as a target of insecticide resistance so as to design an efficient inhibitor compound, and can be used as a target spot for solving the insecticide resistance.
Owner:INST OF PLANT PROTECTION CHINESE ACAD OF AGRI SCI

Immunorejection resistant engineered cells

The present invention relates to an immunosuppressive molecule comprising an immunosuppressive protein binding domain, a transmembrane domain and a costimulatory domain and not comprising a primary signaling domain, wherein the immunosuppressive protein binding domain is selected from an antibody targeting FasL, an antibody targeting IRP60, a ligand of IRP60 or a functional fragment thereof, an antibody targeting SIRP alpha, a ligand of SIRPa or a functional fragment thereof, and wherein the immunosuppressive molecule is capable of reducing immunological rejection of cells of a subject. The invention also relates to engineered cells expressing said immunosuppressive molecules and to compositions comprising the cells. The invention also provides methods of reducing immunological rejection using the immunosuppressive molecules.
Owner:NANJING BIOHENG BIOTECH CO LTD

Chimeric antigen receptor compositions, car-mast cells formed therefrom, and methods of use thereof

Fusion proteins including (a) a mast cell intracellular signaling domain; and (b) an amino acid sequence that is heterologous to the mast cell intracellular signaling domain are provided. In some embodiments, (a) includes the intracellular domain of IgE receptor (FcεRI), a cytokine receptor (c- KIT), a G-protein-coupled receptor, or a toll-like receptor expressed in mast cells, or functional fragment or variant thereof. In some embodiments, the amino acid sequence of (a) includes an ITAM sequence. In preferred embodiments, the fusion proteins are chimeric antigen receptors (referred to as "CAR-mast"), that include a transmembrane domain and an extracellular domain that targets an antigen. Nucleic acids encoding the fusion proteins, and mast cells including or expressing the nucleic acids and / or fusion proteins are also provided, as are methods of the using the same to treat diseases and disorders characterized by expression of the antigen.
Owner:YALE UNIVERSITY

Bispecific chimeric antigen receptor targeting CD117 and CD7 and its application

The present invention relates to a bispecific chimeric antigen receptor targeting CD117 and CD7 and its application, wherein the bispecific chimeric antigen receptor comprises a signal peptide, an antigen binding domain, a hinge region, a transmembrane domain and a signal transduction domain, wherein the antigen binding domain comprises a CD117 binding domain and a CD7 binding domain. The bispecific chimeric antigen receptor provided by the present invention combines targeted antibodies for CD117 and CD7 together, recognizes and binds to two different antigens at the same time, enhances the targeted elimination ability of malignant cells, and by acting on hematopoietic stem cells and immune cells at the same time, can more effectively eliminate tumor cells in the receptor, while retaining or reconstructing normal hematopoietic and immune functions.
Owner:GUANGZHOU BIO GENE TECH CO LTD

Synthetic t cell receptors for enhancing memory (STEM) t cells using new transmembranes and signaling domains

The present invention relates to chimeric antigen receptors (CAR) containing TCR hinge and transmembrane domains. The present invention also relates to using transmembrane pairing to enhance the stability and specificity of dual antigen CARs. The present invention also relates to new CARs containing transmembrane and signaling domains from cytokine receptors.
Owner:IMMUNOVA THERAPEUTICS LLC

Chimeric cytokine receptor for activating lymphocytes by using soluble immunosuppressive molecules and application of chimeric cytokine receptor in tumor treatment

The invention relates to the field of biological medicines, in particular to a chimeric cytokine activated receptor for activating lymphocytes by using soluble immunosuppressive molecules and application of the chimeric cytokine activated receptor in tumor treatment. The chimeric cytokine activation receptor and a chimeric antigen receptor for recognizing tumor antigens are connected in parallel to form a co-expressed polycistron structure. Wherein the chimeric cytokine activation receptor comprises an scFv structural domain, a transmembrane structural domain and a cytokine chimeric activation structural domain which specifically recognize and bind soluble immunosuppressive molecules. The CAR-NK cell can specifically recognize soluble inhibitory factors in the tumor microenvironment and improve the in-vivo and in-vitro anti-tumor efficacy of the CAR-NK cell, and can be used for treating solid malignant tumors.
Owner:THE NAVAL MEDICAL UNIV OF PLA

Synthetic cytokine receptors

PCT designated stage expiredWO2025007073A2Polypeptide with localisation/targeting motifImmunoglobulin superfamilyInterleukin-9 receptorWhite blood cell
Provided herein are synthetic cytokine receptors, wherein each synthetic cytokine receptor comprises an extracellular domain, a transmembrane domain, and an interleukin 9 receptor (IL-9R) intracellular domain. Also provided herein are engineered cells expressing one or more such synthetic cytokine receptors.
Owner:DISPATCH BIOTHERAPEUTICS INC

Screening method for signal peptides for efficient expression and secretion of heterologous polypeptides in mammalian cells - Patents.com

The present disclosure is directed to a method for screening signal peptides for efficient expression and secretion of heterologous polypeptides in mammalian cells, comprising: providing a pool of viral expression vectors encoding a polypeptide of interest comprising a variety of candidate signal peptides, wherein each viral expression vector of the pool comprises at least a polynucleotide encoding a fusion protein, the polynucleotide comprising: (i) a promoter, (ii) a sequence encoding a signal peptide, (iii) a sequence encoding a polypeptide of interest, (iv) optionally, a sequence encoding an epitope tag, and (v) a sequence encoding a C-terminal signal peptide for glycosylphosphatidylinositol (GPI) attachment or a sequence encoding a transmembrane domain; hosting the viral vector pool such that each host cell is preferably transformed with only one viral vector from the pool on average. The method includes the steps of transforming a host cell; expressing the fusion protein in the host cell to produce a fusion protein that is anchored to the host cell surface by a GPI or a transmembrane domain of the fusion protein; contacting the host cell with a first binding reagent, preferably an antibody that specifically binds to the target polypeptide; or, if an epitope tag is present in the fusion protein, a first binding reagent that specifically binds to the epitope tag; contacting the host cell with the first binding reagent, which may optionally be labeled with a fluorescent label or other detection means; dividing the transformed host cells into at least two groups based on the fluorescent properties of each host cell; and performing next-generation sequencing on the group of host cells that show the most efficient fusion protein expression to identify the optimal signal peptide for the target polypeptide in the host cell. The present disclosure is also directed to the vector, host cell, or DNA library used in the method.
Owner:ヘルシンギン イリオピスト

Bispecific chimeric antigen receptors targeting CD20 and bcma

The present disclosure provides bispecific chimeric antigen receptors targeting CD20 and BCMA. The CAR may comprise an scFv targeting CD20 and an scFv targeting BCMA, a hinge region, a transmembrane domain, a co-stimulatory region, and a cytoplasmic signaling domain. The chimeric antigen receptors can be used to treat autoimmune disorders or cancer.
Owner:ABELZETA INC

IL-12-CD137 chimeric protein, function-enhanced engineered NK cell as well as preparation and application of IL-12-CD137 chimeric protein and function-enhanced engineered NK cell

The invention belongs to the technical field of bioengineering, and particularly relates to an IL-12-CD137 chimeric protein, a function-enhanced engineered NK cell, and preparation and application thereof. The IL-12-CD137 chimeric protein comprises a signal peptide, an IL-12a protein molecule, a CD137 transmembrane structural domain and a CD137 intracellular structural domain, and has an amino acid sequence as shown in SEQ ID NO: 1. According to the function-enhanced engineered NK cell, the IL-12-CD137 chimeric protein sequence is introduced into an original NK cell, the function-enhanced engineered NK cell expressing Chime-IL12-CD137 is obtained, the amplification capacity and killing capacity of the NK cell can be enhanced, and the function-enhanced engineered NK cell is applied to treatment of tumor and virus-infected diseases of companion animals for the first time.
Owner:GUOKE MINGYAO (SHANDONG) MEDICAL TECHNOLOGY CO LTD

Chimeric autoantibody receptor (CAAR) that binds autoantibodies targeting the central nervous system in neurological autoimmune disease

A chimeric autoantibody receptor (CAAR) that enables targeting of an immune cell to autoantibody producing B cells. The CAAR includes an autoantigen or fragment thereof that is bound by autoantibodies associated with neurological autoimmune disease primarily targeting the central nervous system. Also disclosed is a nucleic acid molecule encoding a chimeric autoantibody receptor (CAAR), the nucleic acid sequence encoding an autoantigen or fragment thereof that is bound by autoantibodies associated with a neurological autoimmune disease primarily targeting the central nervous system, a transmembrane domain, and an intracellular signaling domain, a vector comprising a nucleic acid molecule encoding a chimeric autoantibody receptor (CAAR), a genetically modified immune cell comprising the nucleic acid molecule encoding the CAAR and use of the immune cell in the treatment or prevention of a neurological autoimmune disease primarily targeting the central nervous system, such as an autoimmune encephalopathy or encephalomyelopathy, preferably anti-NMDAR encephalitis.
Owner:DEUT ZENT FUER NEURODEGENERATIVE ERKRANKUNGEN EV +1

Salty and fresh difunctional taste-active peptide as well as preparation method and application thereof

The invention discloses a salty and fresh difunctional taste-active peptide as well as a preparation method and application thereof, and relates to the technical field of biology. The amino acid sequence of the salty and fresh difunctional taste-active peptide is as shown in any one of SEQ ID NO.1-4. According to the invention, a compound protease enzymolysis method is adopted to prepare enzymatic hydrolysate rich in salty and fresh dual-function taste-active peptides, a plurality of salty and fresh dual-function taste-active peptides are identified and screened out by utilizing polypeptiomics and a molecular docking technology, and meanwhile, a transmembrane structure domain of a taste receptor is evaluated and predicted; chemical bonds and docking sites for docking of the salty and fresh difunctional taste-active peptide and the taste receptor are analyzed, key chemical bonds and binding sites for interaction of the salty and fresh difunctional taste-active peptide and the salty receptor are summarized, and the salty taste and umami strength of the salty and fresh difunctional taste-active peptide and the salty receptor are evaluated. The salty and fresh dual-function flavor peptide screened by the invention has strong salty taste and fresh taste, can be used as a substitute of sodium salt, and is used for preparing low-salt and low-sodium food. The invention also provides a certain reference for rapidly and simply obtaining the salty and fresh dual-function taste-active peptide.
Owner:SHENZHEN INST OF GUANGDONG OCEAN UNIV

Constitutive cytokine receptors

Provided herein is a recombinant protein comprising a transmembrane domain derived from a transmembrane domain of a wild type erythropoietin receptor (EPOR). Nucleic acid molecules encoding such recombinant proteins, recombinant constructs, vectors and cells containing the nucleic acid molecules, methods of producing such cells and therapeutic uses thereof are also provided.
Owner:GUELL MEDICAL LTD

Chimeric antigen receptor comprising novel co-stimulatory domain and use thereof

The present invention relates to a chimeric antigen receptor, comprising a ligand binding domain, a transmembrane domain, a co-stimulatory domain, and an intracellular signaling domain, wherein the co-stimulatory domain comprises a mutated CD27 intracellular region. The present invention also relates to an engineered immune cell comprising the chimeric antigen receptor, and a use thereof in treatment of diseases, such as cancer, autoimmune diseases, infections.
Owner:HONGKONG BIOHENG BIOTECH LTD

Epcam antibody and Epcam-CAR-T cells

The present invention is directed to a humanized monoclonal anti-human EpCAM antibody, such as a single-chain variable fragment (scFv), comprising VH having the amino acid of SEQ ID NO: 2 and VL having the amino acid of SEQ ID NO: 4. The present invention is also directed to a chimeric antigen receptor fusion protein comprising from N-terminus to C-terminus: (i) a single-chain variable fragment (scFv) of the present invention, (ii) a transmembrane domain, (iii) at least one co-stimulatory domains, and (iv) an activating domain.
Owner:PROMAB BIOTECH +1

Targeted protein degradation system and application thereof

The invention relates to an endoplasmic reticulum-based chimeric protein construct for targeting protein degradation and application thereof, for example, the chimeric protein construct is used for treating cancers, virus infectious diseases, autoimmune diseases, neurodegenerative diseases and the like. The chimeric protein constructs comprise an endoplasmic reticulum-related degradation mechanism protein binding domain and a targeting domain. The ERAD mechanism protein binding domain of the chimeric protein construct may be a transmembrane domain of a viral endoplasmic reticulum resident protein or a functional variant thereof and an endoplasmic reticulum resident domain or a functional variant thereof. The targeting domain of the chimeric protein construct can target any target protein of interest, which can be a natural ligand of the target protein, an antibody that specifically recognizes the target protein, or an antigen-binding fragment thereof. The targeting domain of the chimeric protein construct may also be an antigen that can be specifically recognized by an antibody.
Owner:ST PHI THERAPEUTICS CO LTD

IL5RA cell surface marker

The invention relates to an IL5RA cell surface marker. A cell tag comprising an extracellular region, a transmembrane region, and optionally an intracellular region is provided. The extracellular region comprises an IL5 receptor alpha (IL5Ra) sequence linked to a transmembrane domain, and the recombinant polypeptide cannot function in signal transduction. The cell tag can be operably linked to a transgene. Expression of the cell tag allows for the identification, detection, selection, and ablation of cells expressing the transgene and the cell tag. In some embodiments, the genetically modified host cell comprises a transgene comprising a polynucleotide encoding a chimeric antigen receptor comprising a ligand binding domain and a polynucleotide encoding a cell tag. Pharmaceutical formulations produced by the methods and methods of using the pharmaceutical formulations are also described.
Owner:SONOMA BIOTHERAPEUTICS INC

Use of the CD2 signaling domain in second-generation chimeric antigen receptors

The present invention provides compositions and methods for treating cancer in a human. The invention includes relates to administering a genetically modified T cell expressing a CAR having an antigen binding domain, a transmembrane domain, a CD2 signaling domain, and a CD3 zeta signaling domain. The invention also includes incorporating CD2 into the CAR to alter the cytokine production of CAR-T cells in both negative and positive directions.
Owner:THE TRUSTEES OF THE UNIV OF PENNSYLVANIA

Multivalent interferon particles compositions and methods of use

Disclosed herein are multivalent particles that comprise multiple copies of an interferon (IFN) fusion proteins, wherein fusion protein comprises interferon polypeptide fused to a transmembrane domain and expressed on the surface of the multivalent particle. It also discloses composition and uses of the multivalent particles for treating diseases, disorders, and infections.
Owner:ACHELOIS BIOPHARMA INC

Regulatable cell surface receptors and related compositions and methods

Provided herein are cell surface receptors that include an extracellular binding domain, a transmembrane domain, an intracellular signaling domain, and a protease cleavage site disposed between the extracellular binding domain and the intracellular signaling domain. In certain aspects, the cell surface receptors are engineered cell surface receptors, such as chimeric antigen receptors (CARs). Also provided are cells that include such receptors (e.g., where the cells express the receptors on their surface) and pharmaceutical compositions including such cells. Nucleic acids that encode the cell surface receptors, cells including such nucleic acids, and pharmaceutical compositions including such cells, are also provided. Also provided are methods for regulating signaling of a cell surface receptor, and methods of using the cells of the present disclosure, including methods of using such cells to administer a regulatable cell-based therapy to an individual.
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV